Phase 3 Readout~month

Phase 3 Topline: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemothera

Indication
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Other upcoming events for AXIM

Patent ExpiryPatent/Exclusivity Expiry: VYXEOS
Patent ExpiryPatent/Exclusivity Expiry: KHAPZORY
Patent ExpiryPatent/Exclusivity Expiry: IMKELDI
Patent ExpiryPatent/Exclusivity Expiry: VYKOURA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemothera — AXIM Phase 3 Readout | BioSniper